2型糖尿病合并肾病患者的纵向eGFR轨迹
该研究基于6项临床试验的重复血清肌酐测量数据,用贝叶斯模型计算每位患者eGFR非线性下降的概率。结果显示所有试验中非线性下降的中位概率为0.26,糖尿病试验为0.28,非糖尿病试验为0.09(P<0.01),多数患者eGFR下降呈线性。
要点
- 多数糖尿病和非糖尿病肾病患者eGFR下降呈线性轨迹。
- 糖尿病试验中非线性下降概率高于非糖尿病试验(0.28 vs 0.09,P<0.01)。
- 糖尿病临床试验设计需考虑非线性下降比例。
核心结论
- 在糖尿病和非糖尿病肾病临床试验期间,多数患者eGFR下降大致呈线性,但糖尿病试验中非线性比例较高,设计试验时需考虑。
研究设计与样本
- 纵向观察性研究,纳入6项有重复血清肌酐测量的临床试验,使用贝叶斯模型计算每位患者eGFR非线性轨迹概率。
主要发现
- 所有试验中非线性eGFR下降的中位概率为0.26(IQR 0.13-0.48)。
- 糖尿病试验中位概率为0.28,非糖尿病试验为0.09(P<0.01)。
- 非线性下降概率>50%的患者比例在糖尿病试验为19.3%-31.7%,非糖尿病试验为15.1%-21.2%。
- 基线eGFR较高、男性、糖尿病状态、更陡的eGFR斜率及使用非RASi降压药与非线性轨迹概率更高独立相关。
临床怎么用
- 在糖尿病肾病临床试验设计中,应考虑非线性eGFR下降的比例,避免仅假设线性下降而影响终点评估。
- 临床解读eGFR变化时,需注意糖尿病患者的非线性下降可能性较高。
局限性
- 随访时间相对较短,且未直接测量GFR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In clinical practice and clinical trials, changes in serum creatinine concentrations are used to evaluate changes in kidney function. It has been assumed that these changes follow a linear pattern when serum creatinine concentration is converted to estimated glomerular filtration rate (eGFR). However, the paradigm that kidney function declines linearly over time has been questioned by studies showing either linear or nonlinear patterns. To verify how this impacts on kidney end points in intervention trials, we analyzed eGFR trajectories in multiple clinical trials of patients with and without diabetes. STUDY DESIGN: Longitudinal observational study. SETTING & PARTICIPANTS: 6 clinical trials with repeated measurements of serum creatinine. PREDICTOR: Patient demographic and clinical parameters. OUTCOMES: Probability of nonlinear eGFR function trajectory calculated for each patient from a Bayesian model of individual eGFR trajectories. RESULTS: The median probability of a nonlinear eGFR decline in all trials was 0.26 (interquartile range, 0.13-0.48). The median probability was 0.28 in diabetes versus 0.09 in nondiabetes trials (P<0.01). The percentage of patients with a >50% probability of nonlinear eGFR decline was generally low, ranging from 19.3% to 31.7% in the diabetes trials and from 15.1% to 21.2% in the nondiabetes trials. In the pooled data set, multivariable linear regression showed that higher baseline eGFR, male sex, diabetes status, steeper eGFR slope, and non-renin-angiotensin-aldosterone-system antihypertensives were independently associated with a greater probability of a nonlinear eGFR trajectory. LIMITATIONS: Relatively short follow-up and no measured GFR. CONCLUSIONS: In both diabetes and nondiabetes trials, the majority of patients show a more or less linear eGFR decline. These data support the paradigm that in diabetic and nondiabetic kidney disease, eGFR decline progresses linearly over time during a clinical trial period. However, in diabetes, one should take the nonlinearity proportion into account in the design of a clinical trial.
引用
- Weldegiorgis M, de Zeeuw D, Li L, et al. Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. Am J Kidney Dis. 2017. PMID: 29153995. doi:10.1053/j.ajkd.2017.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。